Trial reportDigestive diseases and sciences2011
The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.
Trial report in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.Hepatology international · 2016Pooled it
- Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis.Journal of the renin-angiotensin-aldosterone system : JRAASPooled it
- Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.Trials · 2014Trial
- Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective.Frontiers in pharmacology · 2025Review
- The Renin-Angiotensin System in Liver Disease.International journal of molecular sciences · 2024Review
- The role of hepatic microenvironment in hepatic fibrosis development.Annals of medicine · 2022Review
- Molecular and cellular mechanisms of liver fibrosis and its regression.Nature reviews. Gastroenterology & hepatology · 2021Review
- Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatology international · 2021Review
- Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study.Current therapeutic research, clinical and experimental · 2021Article
- Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response.International journal of molecular sciences · 2020Review
- Review
- Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.The Korean journal of internal medicine · 2018Review
- Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.Canadian journal of gastroenterology & hepatology · 2018Review
- Hepatic Fibrosis in Dogs.Journal of veterinary internal medicine · 2018Review
- Novel treatment options for portal hypertension.Gastroenterology report · 2017Article
- Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Digestive diseases and sciences · 2016Review
- Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.Digestive diseases and sciences · 2016Article
- Evidence-based clinical practice guidelines for liver cirrhosis 2015.Journal of gastroenterology · 2016Review
- Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- Ethyl Acetate Fraction of Amomum xanthioides Exerts Antihepatofibrotic Actions via the Regulation of Fibrogenic Cytokines in a Dimethylnitrosamine-Induced Rat Model.Evidence-based complementary and alternative medicine : eCAM · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundTherapies that can slow the progression of liver fibrosis in chronic liver disease are needed. Evidence suggests that the renin-angiotensin system (RAS) contributes to inflammation and fibrosis in chronic liver disease. Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties.
aimsIn this study, we evaluated the effects of continuous ACEi/ARB use for 3.5 years on histological liver fibrosis progression in the HALT-C Trial cohort.
methodsIn the HALT-C Trial, subjects with chronic hepatitis C and advanced hepatic fibrosis (Ishak stage ≥3) underwent serial liver biopsies at baseline, 1.5 years, and 3.5 years after randomization. The primary outcome was a ≥2-point increase in Ishak fibrosis score in at least one of the two serial biopsies. Sixty-six subjects were continuously taking ACEi/ARBs over the observation period, 126 were taking other antihypertensive medications, and 343 subjects took no antihypertensive medications.
resultsThe three groups were similar in baseline fibrosis scores, and the two groups being treated with antihypertensives were taking a similar number of antihypertensive medications. Fibrosis progression occurred in 33.3% of the ACEi/ARB group, 32.5% of the other antihypertensive medications group, and in 25.7% of subjects taking no antihypertensive medications. No significant associations between ≥2-point increases in fibrosis scores and continuous ACEi/ARB use were apparent at either 1.5 or 3.5 years in diabetes-adjusted and unadjusted odds ratios.
conclusionsACEi/ARB therapy did not retard the progression of hepatic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.